SEC Filings
Rocket Lab financial disclosures with AI-powered intelligence
Updated 4 days ago
Brief
Director Merline Saintil disposed of a total of 108,500 shares in two transactions: contributing 96,000 shares to an exchange fund at $86.58 per share and selling 12,500 shares automatically under a Rule 10b5-1 plan at $90 per share. This represents a neutral signal, as the sales were part of a pre-arranged trading plan with one discretionary element.
Key Telemetry
- • Total shares disposed (108,500) represent about 28% of pre-transaction direct holdings (388,529 shares), indicating a significant reduction in her position.
- • The 12,500-share sale was executed automatically under a Rule 10b5-1 plan adopted in September 2025, while the 96,000-share contribution to an exchange fund lacked such a plan association.
- • Transactions occurred at prices of $86.58 and $90, but without 52-week context or market data, bullish/bearish price signals cannot be determined.
- • No specific timing ties to earnings, announcements, or known events around January 2026.
Brief
Form 144 filed by Rocket Lab director Merline Saintil for the proposed sale of 12,500 common shares via Morgan Stanley, valued at $1.08M. This notice, dated Jan 14, 2026, relates to RSUs acquired in August 2023 and is part of a broader selling pattern. For investors, it signals ongoing insider liquidity events but does not indicate new negative information per the 10b5-1 certification.
Key Telemetry
- • Merline Saintil (Director) proposes selling 12,500 RKLB shares on Jan 14, 2026, with an aggregate market value of $1.08 million.
- • Shares originated from 12,500 RSUs acquired on Aug 22, 2023, at no cost (nature of acquisition: Restricted Stock Units).
- • This is part of a 10b5-1 plan adopted on Sep 17, 2025, with prior 3-month sales of 35,000 shares for ~$2.05M (Dec 4, 12, 17, 19, 2025).
- • Sale facilitated by Morgan Stanley via NASDAQ; insider represents no material adverse non-public information as of plan adoption.
- • Director relationship confirmed; total outstanding shares ~534.16M, indicating minimal dilution impact (0.002% of float).
Brief
Rocket Lab COO Frank Klein executed a pre-planned sale of 100,000 common shares on January 2, 2026, via a Rule 10b5-1 trading plan established September 19, 2025. Shares were sold across multiple transactions at weighted average prices ranging from $67.20 to $76.05, reducing Klein's direct beneficial ownership to 1,169,487 shares. The filing confirms no changes to Neutron development timeline or launch manifest disruptions.
Key Telemetry
- • 100,000 shares sold: 9 discrete transactions executed January 2, 2026, via pre-arranged 10b5-1 plan
- • Price execution: Weighted averages from $67.20-$76.05, demonstrating market-based liquidity without signaling
- • Post-ownership: 1,169,487 shares retained, representing 0.23% of Rocket Lab's ~507M shares outstanding
- • Plan adoption: 10b5-1 trading plan established September 19, 2025, confirming long-term liquidity strategy
- • No operational impact: Filing contains zero references to launch delays, Neutron development issues, or guidance changes
Brief
CFO Adam Spice executed a multi-tranche equity sale of 1.1M shares on Jan 5, 2026, following a Rule 10b5-1 plan adopted September 19, 2025. The sales occurred at prices between $71.49 and $78.24 per share, generating approximately $84M in gross proceeds. Spice simultaneously exercised 731,330 stock options at $1.09 per share, increasing his direct common stock ownership to 1.6M shares post-transaction.
Key Telemetry
- • Option Exercise: 731,330 shares acquired at $1.09 strike price, representing $51.4M intrinsic value captured
- • Share Disposition: 1.13M shares sold at $71-78 range, generating ~$84M gross proceeds via Rule 10b5-1 plan
- • Post-Transaction Ownership: 1.6M shares held directly by CFO after net exercise of 731K options and 1.13M share sale
- • Plan Timing: Trading plan adopted September 19, 2025, providing 2.5-month lookback before execution
- • Vesting Schedule: Original 2018 option grant with 4-year monthly vesting (1/4 at 1-year, 1/48 monthly thereafter)
Brief
Form 144 filed by Officer Adam C Spice for the sale of 1,365,665 common shares on 01/05/2026, with an aggregate market value of $103,776,883.35 on NASDAQ. This follows prior sales of 62,627 shares in November 2025 for $2,545,894.61, indicating a planned liquidity event under a Rule 10b5-1 adoption date of 09/19/2025.
Key Telemetry
- • Share Volume: 1,365,665 common shares to be sold, representing 0.26% of 534,156,333 outstanding shares, with an aggregate market value of $103,776,883.35 on 01/05/2026.
- • Acquisition Details: Securities acquired via stock option exercises—731,330 shares on 01/05/2026 and 634,335 on 09/18/2025 from the issuer for cash, indicating options exercise at current valuations.
- • Prior Sales: 62,627 shares sold in November 2025 (46,994 on 11/24 at $1,920,188.47; 15,633 on 11/22 at $625,706.14), totaling $2.5M in gross proceeds, consistent with a pre-planned 10b5-1 strategy adopted 09/19/2025.
- • Filing Context: Filed as LIVE by Adam C Spice (Officer relationship), brokered by Morgan Stanley, via NASDAQ, with no test status, emphasizing executive confidence through Rule 144 compliance.
- • Operational Implication: No direct launch or financial data disclosed; the 10b5-1 plan adoption suggests routine insider diversification without signaling material adverse information on Electron or Neutron programs.
Brief
Rocket Lab officer Frank Klein filed a Form 144 on January 2, 2026, to sell 100,000 shares of common stock with an estimated market value of $6,976,000. This planned liquidation follows the vesting of restricted stock units and follows approximately $2.1M in sales conducted over the previous three months.
Key Telemetry
- • Proposed Sale: 100,000 shares of common stock with an aggregate market value of $6,976,000.
- • Recent Sell History: 51,254 shares sold between November 24 and November 26, 2025, for total proceeds of $2,097,131.73.
- • Acquisition Methodology: Shares were acquired via RSU vestings on 11/22/2024, 09/15/2025, and 11/22/2025.
- • Structural Planning: Sale executed under a 10b5-1 trading plan adopted on September 19, 2025, providing a regulatory safe harbor.
Brief
On 12/23/2025, Director Edward H. Frank disposed of 2,500 common shares via sale at $77.3887 per share and 5,000 shares via gift. Following these transactions, his direct beneficial ownership stands at 142,504 shares.
Key Telemetry
- • Transaction Date: 12/23/2025 (Sale: 2,500 shares @ $77.39; Gift: 5,000 shares)
- • Ownership Impact: Direct stake reduced to 142,504 common shares post-transaction
- • Filing Type: Form 4 (non-10b5-1), filed 12/30/2025 by Director Edward H. Frank
- • Security: Rocket Lab Common Stock (RKLB), no derivative securities involved
Brief
Director Alexander R. Slusky acquired 20,000 shares of Rocket Lab common stock on December 23, 2025, increasing his direct beneficial ownership. This transaction follows the company's ongoing efforts in launch operations and vehicle development.
Key Telemetry
- • Director Alexander R. Slusky acquired 20,000 shares of Rocket Lab common stock on 12/23/2025.
- • Direct beneficial ownership increased to 68,849 shares post-transaction.
- • Total beneficial ownership, including indirect holdings, is 603,524 shares.
- • Transaction reported under SEC Form 4, standard for insider equity changes.
Brief
Rocket Lab's Chief Financial Officer, Adam C. Spice, acquired 1,470 shares of common stock on December 23, 2025. This transaction was made under a pre-arranged trading plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions. Mr. Spice's total direct beneficial ownership now stands at 1,993,903 shares.
Key Telemetry
- • CFO Adam C. Spice acquired 1,470 shares of common stock on 12/23/2025.
- • Transaction executed under a Rule 10b5-1(c) trading plan.
- • Acquisition price reported as $0.0, indicating an award or grant.
- • Mr. Spice's direct beneficial ownership is now 1,993,903 shares.
Brief
Rocket Lab Director Edward H. Frank, through Fidelity Brokerage Services, has filed a Form 144 to sell 2,500 shares of common stock. The intended sale, valued at approximately $193,471.75, is scheduled for December 23, 2025, and will occur on the NASDAQ.
Key Telemetry
- • Insider Sale: Director Edward H. Frank plans to sell 2,500 common shares.
- • Sale Value: Aggregate market value of the proposed sale is $193,471.75.
- • Acquisition Basis: Shares were acquired through restricted stock vesting on 09/02/2023 as compensation.
- • Sale Date: The approximate date of sale is set for 12/23/2025.
- • No Prior Sales: No securities of the issuer were sold by the reporting person in the past 3 months.